VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Status:
Recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
Patients enrolled to the study will have chronic lymphocytic leukemia (CLL) and are actively
receiving ibrutinib. Patients will have either been receiving ibrutinib for one year without
having had a complete response or patients will have developed a resistance mutation to
ibrutinib. This study will have two parts, a dose escalation part and a dose expansion part.
In the dose escalation part, the maximum tolerated dose (MTD) of the combination of VAY736
with ibrutinib will be determined. Once determined, the dose expansion part of the study will
begin.